Home
About
Overview
Sharing Data
ORCID
Help
History (1)
TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.
TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 2011 Apr 01; 29(10):1373-81.
View in:
PubMed
subject areas
Adolescent
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
Cytogenetic Analysis
Dioxygenases
Disease-Free Survival
DNA Mutational Analysis
DNA-Binding Proteins
Female
Gene Expression Profiling
Gene Expression Regulation, Leukemic
Genetic Predisposition to Disease
Humans
Kaplan-Meier Estimate
Leukemia, Myeloid, Acute
Male
MicroRNAs
Middle Aged
Mutation
Phenotype
Polymerase Chain Reaction
Proportional Hazards Models
Proto-Oncogene Proteins
Risk Assessment
Risk Factors
Time Factors
Treatment Outcome
United States
Young Adult
authors with profiles
Richard A. Larson